Skip to main content
Premium Trial:

Request an Annual Quote

MiraiBio, Elsevier MDL, William Rich, Gail Page, James Rathmann, John Young, Gene Cartwright


New Products

MiraiBio, a division of Hitachi Software Engineering America, has released MasterPlex QT v2.5, quantitation software for statistical analysis of multiplexed data generated on the Luminex 200 liquid array detection system. The software includes multi-sample charts, three-dimensional depth charts, and intensity maps, and is able to generate weighted four- and five-parameter logistics standard curves, dose-response curves, and residual plots.

Elsevier MDL has released the initial version of its MDL Notebook electronic lab notebook, which allows scientists to store experiment protocols, share hypotheses with colleagues, and legally document discoveries.


Movers & Shakers

William Rich will retire as CEO of Ciphergen, and as a member of the company's board of directors, effective Dec. 31. Gail Page will be promoted from president and COO to president and CEO of the company.

James Rathmann has been appointed executive chairman of Ciphergen, and John Young will act as the company's lead outside director. (see story, this issue, for further details).

GE Healthcare named Gene Cartwright as president of its Molecular Diagnostics business to lead the development of the in-vitro clinical diagnostics business.

He will be based in Piscataway, NJ.

Cartwright was previously at Abbott Laboratories as vice-president of strategic programs for its molecular diagnostics business. He received his PhD in chemistry from Stanford University.

NOTE: This is the last issue of ProteoMonitor to be published in 2005. We will resume our normal publishing schedule on Jan. 6, 2006.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.